Monthly Newsletter

Join SMi at the 12^th annual Pain Therapeutics conference, which will be held on 21^st & 22^nd May 2012 in London, UK.

Pain is an incredibly hot topic as it affects all illnesses and all people, in many different ways. This makes it an incredibly lucrative business and one that has not yet been explored in the pharmaceutical industry to its full potential. Pain is also the most common reason patients seek medical care, as it affects the quality of life many people experience and has significant sensory and emotional components.

Whilst advances have been made in pain management, few significant ones have occurred, making it harder in recent years to get analgesics to market. In the current economic climate, this makes it even more imperative for companies to improve their R&D methods so that drugs being put forward for clinical trials have the best chance of success.

With only 1 week left, this is your last chance to register for this exciting event! Don't miss out and book today!

 Hear key presentations from industry-leading experts:

• Chas Bountra, Professor of Translational Medicine, Head, Structural Genomics Centre Oxford University
• Jonathan Stewart, Disease Area Head, Neuroscience, Immunology and Pain, Bristol-Myers Squibb
• Jason Witherington, Head of Chemistry, GlaxoSmithKline
• Philip Kym, Associate Director II Pain Discovery Research, Abbott
• Dave Shelton, Senior Director, Pfizer Global Research & Development
• Jaymin Upadhyay, Senior Scientist II Translational Sciences, Abbott Laboratories
• Ralf Baron, Director of Pain Research and Therapy, Schleswig-Holstein

 Network with our registered delegates:

Grünenthal GmbH; NsGene; Pfizer; Astellas Pharma Kft; Aquila BioMedical; Helsinn Healthcare; Allergan; Mundipharma International; Vetoquinol; Orion Corporation; University of Bristol; Klinik fa+r Neurologie; Ricerca Biosciences; Apposite Capital...

For further information click here